[25] Shaamash et al. [27] conducted a prospective, controlled, randomized trial (n = 320) comparing the levonorgestrel-20 µg intrauterine system Mirena (Bayer HealthCare Pharmaceuticals ...

Use of long-acting, reversible contraceptives is associated with an increased risk of certain cancers, a study suggests.

The company's first product, the Juveena Hydrogel System, is designed for preventing the formation or reformation of intrauterine adhesions following transcervical gynecological procedures.